Abbreviations:

AD, Alzheimer\'s disease; APP, amyloid protein precursor; Aβ, amyloid β protein

INTRODUCTION {#sec1-1}
============

Alzheimer\'s disease (AD) is pathologically characterized by senile plaques, neurofibrillary tangles and death of nerve cells, in addition to diffuse cortical atrophy. The well-accepted amyloid β protein (Aβ) hypothesis assumes that abnormally increased Aβ is the main cause of senile plaque formation. The amyloid cascade reaction induced by Aβ fragment aggregation and deposition is an important process in AD pathology. Aβ can produce neurotoxicity through direct or indirect pathways, resulting in neuronal degeneration or death and learning and memory impairment. Under normal culture conditions in AD cell models, the mRNA for amyloid protein precursor (APP) is present at high levels. The translated APP proteins can be converted to Aβ, leading to cell toxicity.

Compound Danshen tablets are composed of *Radix Salviae Miltiorrhizae, Radix Notoginseng*, and *Borneolum Syntheticum*. They can improve circulation in cardio-cerebral vessels. The main components include tanshinone, salvianolic acid, A, B, C, notoginsenoside R~1~, ginsenoside Rb~1~, ginsenoside Rg~1~, and ginsenoside Rd. In a previous study from our group, compound Danshen tablets were shown to prevent and ameliorate AD-like symptoms in AD rats, improving their spatial cognitive impairment, reducing excitatory amino acid glutamic acid content and inhibiting Aβ production\[[@ref1]\]. Recent evidence indicates that compound Danshen tablets can enhance vascular growth factor expression around the infarction in rats with acute brain ischemia and that it can promote nerve cell repair\[[@ref2]\]. Tanshinone can inhibit excess Aβ deposition and attenuate Aβ-induced neurotoxicity.

In the present study, an APP transgenic AD cell model was treated with compound Danshen tablets and donepezil to investigate the effects of the tablets on APP expression, and compare these effects with those of donepezil.

RESULTS {#sec1-2}
=======

Serum total RNA purity analysis {#sec2-1}
-------------------------------

Sprague-Dawley rats were intragastrically perfused with donepezil and compound Danshen tablets to prepare sera containing each treatment. Groupings are shown in [Table 1](#T1){ref-type="table"}. Total RNA was extracted from AD model cells using the one-step guanidinium thiocyanate method and the purity of extracted RNA was determined. As shown in [Table 1](#T1){ref-type="table"}, the absorbance ratio of 260 nm to 280 nm for the RNA from each group ranged from 1.6 to 2.1, indicating high purity of the RNA extracted from each group.

###### 

Total RNA determination results (*x̄*±*s*, *n*=5)
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Effects of compound serum containing compound Danshen on APP mRNA expression in an AD cell model {#sec2-2}
------------------------------------------------------------------------------------------------

After being cultured for 72 hours, APP transgenic cells were treated with normal rat serum (blank serum group), donepezil-containing serum × 1 (donepezil 5.8 mg/kg), and compound *Danshen* tablets at 157.5, 315.0, 630.0, and 1 260.0 mg/kg, to prepare compound *Danshen* tablets-containing serum × 0.5, 1.0, 2.0, and 4.0, respectively.

Following electrophoresis, APP reverse transcription-PCR products were observed under an ultraviolet lamp ([Figure 1](#F1){ref-type="fig"}). PCR product agarose gel electrophoresis was scanned and data were analyzed using Kodak 2.0 software ([Table 2](#T2){ref-type="table"}). The results showed that APP mRNA expression was higher in cells treated with sera containing donepezil and compound *Danshen* compared with those treated with blank serum (*P* \< 0.01, *P* \< 0.05). However, the level of APP mRNA expression was lower in cells treated with sera containing compound *Danshen* and donepezil compared with the blank serum group after culture for 24 and 48 hours (*P* \< 0.01). No significant difference was found between the donepezil and compound *Danshen* tablet groups (*P* \> 0.05).

![Amyloid protein precursor (APP) mRNA expression in the transgenic cell model of Alzheimer\'s disease following compound *Danshen* tablet treatment.\
Lanes 1--6: Blank, cells treated with sera containing compound *Danshen* ×0.5, 1.0, 2.0, and 4.0 and donepezil following administration for 24 hours;\
Lanes 7--12: Blank, cells treated with sera containing compound *Danshen* ×0.5, 1.0, 2.0, and 4.0 and donepezil following administration for 48 hours;\
Lanes 13--18: Blank, cells treated with sera containing compound *Danshen* ×0.5, 1.0, 2.0, and 4.0 and donepezil following administration for 72 hours.](NRR-7-659-g002){#F1}

###### 

Quantitative analysis of amyloid protein precursor mRNA expression in each group
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DISCUSSION {#sec1-3}
==========

The HEK293 cell strain is derived from human embryonic kidney epithelial cells. It has been frequently used in transfection experiments owing to their high efficiency for transfection and culture. Stably transfected HEK293 cells can express secreted proteins or membrane proteins within or outside the cells. In the present study, we transfected HEK293 cells with pcDNA3.1/APP595/596 plasmid to construct an AD cell model with overexpression of Aβ protein.

A previous study from our group showed that various components in compound *Danshen* tablets can intervene in AD processes through different pathways. For example, tanshinone significantly improves learning and memory impairment in rats following intrahippocampal injection of Aβ, protects the cholinergic system in AD-like rats, regulates nitric oxide synthase expression and antagonizes oxidation and inflammation\[[@ref3][@ref4]\]. These results suggest that tanshinone might inhibit excess Aβ deposition and attenuate Aβ neurotoxicity. Tanshinone IIA can increase cortical and hippocampal glutamic acid and gamma-aminobutyric acid content in mice with vascular dementia, decrease malondialdehyde production, increase superoxide dismutase and glutathione peroxidase activities\[[@ref5]\], and inhibit apoptosis of nerve cells\[[@ref6]\]. In the present study, the APP mRNA level was high in our cell model. *Danshen* can significantly improve spatial cognitive impairments in rats with unilateral temporal lobe ischemic damage\[[@ref7]\]; salvianolic acid can ameliorate brain ischemia and inhibit glutamic acid release\[[@ref8]\]. The main component of *Radix Notoginseng*, triterpenoid saponin, is similar to ginsenoside. Modern studies have shown that panax notoginseng fraction B can upregulate muscarinic receptor density\[[@ref9]\], inhibit Aβ production and improve hippocampal acetylcholine release\[[@ref10]\]. *Panax notoginseng* saponins can attenuate Aβ-induced cytotoxicity and promote cell process growth, thereby antagonizing the progression of senile dementia\[[@ref11]\]. Panaxsaponin exhibits evident protection for learning and memory injury\[[@ref12][@ref13]\]. *Broneolum syntheticum* is used as an adjuvant drug in this prescription; it can induce resuscitation, activate consciousness, improve blood-brain barrier permeability, increase drug concentrations in the brain and enhance drug neuropharmacologic actions\[[@ref14]\]. A previous study showed that compound *Danshen* tablets significantly improve learning and memory function in experimental AD rats and inhibit Aβ production in the brain\[[@ref15]\]. In the present study, pretreatment of cells with sera containing compound *Danshen* significantly reduced APP mRNA expression in AD cells and decreased APP and Aβ protein synthesis.

The dose-effect of Chinese medicine, especially compounds, is not obvious. According to serum pharmacology, 7-day administration can enable steady plasma-drug concentrations to be reached. However, the differences among doses remain poorly understood. Further studies should utilize high performance liquid chromatography for serum detection. In addition, the present study was performed at the gene level, so future studies should focus on protein levels.

The results of the present study show that compound *Danshen* tablets can downregulate APP mRNA expression in a cell model of AD, possibly attenuating AD progression. Further randomized, double-blind, multicenter clinical studies are needed to verify these results.

MATERIALS AND METHODS {#sec1-4}
=====================

Design {#sec2-3}
------

*In vitro* neuropharmacology experiment.

Time and setting {#sec2-4}
----------------

The experiment was performed at the Laboratory of Molecular Biology, Xiangya Medical College of Central South University, China between October 2010 and March 2011.

Materials {#sec2-5}
---------

### Animals {#sec3-1}

A total of 30 Sprague-Dawley rats, aged 12-24 hours, weighing 8-12 g, of either gender, were provided by the Laboratory Animal Center of Hunan University of Traditional Chinese Medicine (license No. SCXK (Xiang) 2009-0004). Experimental procedures were performed in accordance with the *Guidance Suggestions for the Care and Use of Laboratory Animals*, published by the Ministry of Science and Technology of China\[[@ref16]\].

### Plasmids {#sec3-2}

pcDNA3.1/APP plasmid was graciously provided by Pittsburgh University, USA and Department of Neurology, Xiangya Medical College of Central South University, China. The plasmid has a product size of 7.6 kb, and carries 2.088 bp of the APP695 cDNA between *Hind* III and *Xba* I restriction sites.

### Cells {#sec3-3}

HEK293 cells were provided by the Laboratory of Molecular Biology, Xiangya Medical College of Central South University, China.

### Drugs {#sec3-4}

Compound *Danshen* tablets were provided by Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Co., Ltd., Guangzhou, China. (batch No. 080401; composed of *Radix Salviae Miltiorrhiae* 450 g, *Radix Notoginseng* 141 g, and *Broneolum Syntheticum* 8 g; *Radix Salviae Miltiorrhiae* was extracted using alcohol; a total of 1 000 tablets were made, each of 0.3 g containing 0.67 mg of tanshinone IIA, 8.2 mg of salvianolic acid, 0.53 mg of notoginsenoside R1, 6.5 mg of ginsenoside Rb1, 7.8 mg of ginsenoside Rg1, and 0.46 mg of ginsenoside Rd). A 1.575% solution was prepared for use. Donepezil hydrochloride tablets were purchased from Shaanxi Ark Pharmaceutical Co., Ltd., Shaanxi Province, China (No. H20030583, 100801053).

Methods {#sec2-6}
-------

### Preparation of serum containing compound Danshen {#sec3-5}

According to a previously described method\[[@ref17]\], the dose of administration was based on the daily clinical dose for adults (mg/kg converted to mg/m^2^): the daily dose of compound *Danshen* tablets for one rat was 315.0 mg/kg and that for donepezil was 5.8 mg/kg. The 30 rats were randomly assigned to a blank serum group and five drug-containing serum groups, with five animals in each group. Donepezil was used as positive control (cholinphospholipid enzyme inhibitor) × 1 (5.8 mg/kg). The concentrations of compound *Danshen* in serum × 0.5, 1, 2, and 4 were 157.5, 315.0, 630.0, and 1 260.0 mg/kg, respectively; rats in the blank serum group were given the same volume of normal saline, once a day for 7 consecutive days, so no compound *Danshen* was present in their sera. Blood was extracted from the abdominal aorta 1 hour after the final administration, and sera were isolated. Complement was deactivated at 56°C for 30 minutes. Serum was filtrated through a microporous membrane (Jinteng, Tianjin, China), packaged, and stored at -20°C.

### Extraction and verification of pcDNA3.1/APP595/596 plasmid {#sec3-6}

pcDNA3.1 APP plasmid was extracted according to a previously described method\[[@ref16]\] and verified by Shanghai Sangon, China. Sequencing results showed that, in addition to the mutations within amino acid codons 595 and 596 (described previously), there was an unexpected mutation at the fourth basic set (C→G at position 2 088 bp in the Appc DNA sequence), which would influence amino acid expression, Leu→Val.

### HEK293 cell culture {#sec3-7}

HEK293 cells were cultured in high-glucose Dulbecco\'s modified Eagle\'s medium containing 10% fetal bovine serum in 5% CO~2~, under saturated humidity at 37°C, and trypsinized (0.25%). Cells adhered like epithelial cells. Cells in the logarithmic phase were selected for experiments.

### Establishment of AD transgenic cell model {#sec3-8}

pcDNA3.1/APP595/596 plasmid was transfected into HEK293 cells using calcium acid phosphate transfection\[[@ref18]\]. Briefly, 1 μg of DNA and 10 μL of CaCl2 (2.5 M), made to a 100-μL solution with sterile water was mixed with 100 μL of 2 × PBS (pH 6.95) and stored at room temperature for 20-30 minutes, then mixed evenly every 10 minutes. The above system was slowly aliquoted into the wells of a 6-well plate, mixed and left at room temperature for 30-50 minutes, before the addition of culture medium containing 10% fetal bovine serum. Cells were cultured in 5% CO~2~ at 37°C. The culture medium was replaced at 2 days, washed with serum-free Dulbecco\'s modified Eagle\'s medium, twice, and cultured with culture medium containing 10% fetal bovine serum. After 3 days, selective culture medium containing 800 μg/mL G418 was used to screen stably transfected clones. After 10-14 days, the clones were screened using G418. Clonal cells were transferred and expanded.

### Interventions {#sec3-9}

After the transgenic AD cell model had been in culture for 72 hours, the blank serum group was treated with normal rat serum; the donepezil group was treated with donepezil-containing serum × 1 (5.8 mg/kg); and the compound *Danshen* tablet groups were treated with sera containing compound *Danshen* × 0.5, 1, 2, and 4, followed by additional culture for 24, 48 and 72 hours for all groups.

### Reverse transcription-PCR for APP mRNA expression in the AD transgenic cell model {#sec3-10}

APP mRNA expression levels were determined using reverse transcription-PCR and PCR primer sequence is shown as follows:
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cDNA synthesis:
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The solution was placed in a 1.5-mL Eppendorf centrifuge tube, stored at 42°C for 60 minutes, cooled on ice, centrifuged for seconds, and subjected to PCR. The PCR system was constructed using 0.5-mL sterile micro centrifuge tubes.

PCR system for amplifying target gene:

![](NRR-7-659-g006.jpg)

The centrifuge tubes were placed in a thermal cycler. PCR amplification was performed using the T-Gradient PCR system (Whatman Biometra, Germany). PCR conditions were as follows:

![](NRR-7-659-g007.jpg)

PCR products were placed on ice. Products (10 μL) were electrophoresed in 1% agarose gels containing 0.5 μg/mL ethidium bromide for detection. Results were analyzed using Kodak 2.0 software (Rochester, NY, USA). The gray scale ratio of APP gene to APP was used to represent relative APP mRNA expression.

### Statistical analysis {#sec3-11}

Measurement data are expressed as means ± SD. Data were analyzed using SPSS version 17.0 software (SPSS, Chicago, IL, USA). Data were subjected to tests of normality and normal distribution. Comparisons of means among groups were performed using one-way analysis of variance; paired comparisons of means among groups were performed using the least significant difference-t test. For heterogeneity of variance, Dunnett\'s T3 method was used. A value of *P* \< 0.05 was considered to represent statistical significance.
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